As of Nov 19, 2026, 1 of 2 active firms rate IRMD a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IRMD EPS & revenue forecast
EPS · NEXT QUARTER
$0.58
Range $0.56 – $0.61 · 3 analysts · +18% YoY
Next period, 3 analysts expect Iradimed Co to earn $0.58 a share (range $0.56 – $0.61), versus $0.49 a year earlier. Full-year consensus is $2.10, growing to $2.44 the year after.
REVENUE · NEXT QUARTER
$24.9M
Range $24.1M – $25.8M · 3 analysts · +14% YoY
Revenue is expected to reach $24.9M (range $24.1M – $25.8M), +13.5% year-over-year. Full-year consensus is $92.2M, rising to $102.3M next year.
Top analysts covering Iradimed Co
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IRMD.
#1
JW
Jason Wittes
Roth MKM · Rank #382
Buy
$72.00-12.6% to target
Overall win rate
40%
+ Follow
#2
David Saxon
Needham · Rank #426
Neutral
No targeton IRMD
Overall win rate
32%
+ Follow
#3
Frank Takkinen
Lake Street · Rank #514
Buy
$120.00+45.7% to target
Overall win rate
27%
+ Follow
#4
IZ
Ilya Zubkov
Freedom Capital Markets
Buy
$116.00+40.8% to target
Coverage
—
+ Follow
#5
IZ
Ilya Zubkov
Freedom Broker
Buy
$116.00+40.8% to target
Coverage
—
+ Follow
IRMD stock forecast FAQ
What is IRMD's average 12-month price target?+
The 1 active firms with a live target average $116.00 for Iradimed Co over the next 12 months, ranging from a $116.00 high to a $116.00 low, as of Nov 19, 2026.
Is IRMD stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover IRMD?+
2 active firms have a recognized rating on Iradimed Co as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IRMD?+
Among analysts who currently cover IRMD, Jason Wittes of Roth MKM has the strongest overall Quantellect track record (Rank #382). Their current call is Buy with a $72.00 target.
What is Iradimed Co's projected EPS for next quarter?+
The consensus estimate is $0.58 per share (range $0.56 – $0.61) across 3 analysts. Full-year EPS is projected at $2.10, rising to $2.44 the following year.
How much revenue is Iradimed Co expected to report next quarter?+
Consensus revenue is $24.9M (range $24.1M – $25.8M). Full-year revenue is projected at $92.2M, growing to $102.3M next year.
Have analysts been upgrading or downgrading IRMD lately?+
As of Nov 19, 2026, 1 of 2 active firms rate IRMD a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IRMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.